Table 3 Current treatments usage in APD and non-APD patients and treatment response

Current PD oral/transdermal treatments (Possible multiple answers)

N = 60

N = 80

 Oral levodopa/carbidopa or benserazide

55 (92%)

60 (75%)

 Oral dopamine agonists

35 (58%)

48 (60%)

 Apomorphine patch

2 (3%)

0

 Subcutaneous apomorphine rescue injection

2 (3%)

0

 COMT-inhibitors

22 (37%)

6 (8%)

 MAO-B inhibitors

14 (23%)

41 (51%)

 Amantadine

6 (10%)

6 (8%)

 Missing

2 (3%)

0

Current oral/transdermal treatment for PD

N = 60

N = 80

 Patients on only oral/transdermal therapy

40 (67%) ^a

79 (99%)

 Patients on ongoing DAT

18 (30%)

1 (1%)

 Missing

2 (3%)

0

Number of current oral/transdermal treatments

N = 58

N = 80

 1

12 (21%)

21 (26%)

 2

19 (33%)

33 (41%)

 3

20 (34%)

24 (30%)

 4

4 (7%)

2 (3%)

 5

3 (5%)

0

Treatment Response on current treatment (oral/transdermal or DAT)

N = 60

N = 80

 Complete response

12 (20%) ^a

55 (69%)

 Partial response

47 (78%) ^a

24 (30%)

 Too early to assess response

1 (2%)

1 (1%)

Status of DAT in the eligible patients

N = 44 (73%) eligible to DAT

N = 5 (6%) eligible to DAT (1 Missing)

 Ongoing DAT

18/44 (41%)

1/5 (20%)

 Decided at visit to start DAT

9/44 (20%)

0

 No DAT

17/44 (39%)

3/5 (60%)

Type of DAT on 44 eligible APD and on 5 eligible non-APD patients

 DBS

11 (25%)

1 (20%)

 LCIG

7 (16%)

0

 CSAI

0

0

Reasons APD patients were not using DAT (Possible multiple answers)

N = 17

 Age

2 (12%)

  Patient refusal

5 (29%)

 Patient needs more time to decide

10 (59%)

 Cognitive related issues

2 (12%)

 Comorbidities

2 (12%)